At the recent American Society of Hematology annual meeting, researchers presented preclinical data examining how ...

Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets ...

At the recent American Society of Hematology annual meeting, phase I data highlighted a next-generation, CD19-targeted, interleukin-18-secreting "armored" CAR T-cell therapy that is designed to ...

Despite major advances in immunotherapy—including the 2025 Nobel Prize in Physiology or Medicine recognizing advances in peripheral immune tolerance—progress against leukemia has remained limited.

Inflammation covertly rewires the bone marrow, enabling mutated stem cells to rise and setting the stage for future blood disease.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submitted two separate Investigational New Drug (IND ...

The company plans to announce Phase 1b interim data by mid-2026, and the TENACITY-01 study is expected to be completed by late 2028. This timing enables progression to Phase 2 evaluation following ...

A research team at Lund University in Sweden has discovered a mechanism that helps acute myeloid leukemia cells to evade the body's immune system. By developing an antibody that blocks the mechanism, ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...